Anti Tuberculosis Drug Liver Injury (ATLI): A Rare Case Should Manage Promptly

Victor Nugroho Wijaya¹, I Made Suma Wirawan²

¹General Practitioner of Wangaya General Hospital, Denpasar, Bali, Indonesia
²Postgraduate Student of Doctoral Program, of Udayana University, Denpasar, Bali, Indonesia

Abstract: Male, 55 years old with tuberculosis, came to hospital with chief of complaint nausea, and vomiting after taking an oral antituberculosis for one month. Patient with unknown liver cirrhotic before oral antituberculosis started. Icteric on the eyes and laboratory results revealed increased AST, ALT, total bilirubin and decreased liver function. Patient diagnosed with Anti Tuberculosis drug Liver Injury (ATLI) and managed as ATLI protocol. We managed the patient by continuing and reintroduction of an oral antituberculosis treatment with close monitoring of serial liver function.

Keywords: antituberculosis, liver injury, ATLI

1. Background

Tuberculosis (TB) remains a major global health problems. There were an estimated 10.4 million incident TB cases of worldwide in 2015 based on WHO Tuberculosis Report 2016. Indonesia included as number two in six countries accounted for 60% of the global total between India, China, Nigeria, Pakistan, and South Africa. The total TB incidence in Indonesia is 395 (255 – 564) /100,000 with mortality rate of 40 (26–57) / 100,000 in HIV-negative TB group and 10 (7.6 – 13) /100,000 in HIV-positive TB group.

The TB treatment regimen consist of Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E), and Streptomycin (S) as the first line anti TB drug. Despite of the effectiveness of these drugs, they are known to induce various side effects, including liver injury, skin reactions, gastrointestinal, and neurological disorders. The incidence of anti tuberculosis drug liver injury (ATLI) during standard multi-drug TB treatment has been reported varying from 3.0% - 34.14%. ATLI incidence in Saiful Anwar Hospital Malang, Indonesia reported in 5.4% patients.

Patient with liver cirrhosis have immune dysfunction with relative derangements of cell mediated immunity. There is reticuloendothelial system dysfunction, with reduced monocyte spreading, chemotaxis, bacterial phagocytosis, and bacterial killing. Baijalet al found that the prevalence of tuberculosis in patients with liver cirrhosis was fifteen times higher than in the general population in Mumbai, Western India. In this study, we report a case of liver function derangement caused by drug induced in cirrhotic patient admitted in Wangaya General Hospital Denpasar, Bali.

2. Case Presentation

A 55 years old, male, admitted in Wangaya General Hospital with complaints of nausea, fatigue, yellowish skin and on both eyes 3 days before. Loss of appetite was also complained, but he had no vomiting. He had dark urine and pale stools within 3 days. He also had hemoptisis one day before, but only about 10 cc. Fever, muscle aches, or any history of melena were denied. He had loss of weight in one last month about 10 kilograms.

Past history of jaundice is denied. Thereis no seizure and focal neurological deficit. He was diagnosed with pulmonary tuberculosis so he was on the first month of intensive phase of antituberculosis treatment (ATT) in fixed drug combination form (Isoniaziid (INH) 300 mg, Rifampicin (RIF) 600 mg, Pirazinamid (PZA) 1600 mg, and Ethambutol (EMB) 1100 mg). Other medications and traditional herbs consumption is denied. He had long term smoking habit one pack per day. Alcoholic drinking habit was none, no history of injecting drug user and blood transfusion recipient.

On physical examination, he has shortened attention span, hypsomnia, lack of awareness, mild confusion, and looked very weak. Vital signs were in normal range. His body was thin and malnourished with yellowish coloured skin. Both of sclera and anterior part of tongue were icteric. He felt pain on palpation on right hypochondriac and epigastric area of abdomen. There was slight hepatomegaly, but no splenomegaly is found. Cardiac and pulmonary examination were sound. Peripheral edema and asterixis were absent.

Laboratory examination revealed derangement of liver function test with high level of alanine transferase (ALT) and aspartate transferase (AST), 107 U/L and 144 U/L, respectively. But normal alkaline phosphatase (ALP) 94 U/dL, and gamma glutamyl transferase (GGT) 50 U/L. Total bilirubin is high (18.15 mg/dL) with direct bilirubin predominant (10 mg/dL). Total protein was low (4.8 gr/dL).
with low albumin 1.5 gr/dL. Prolonged prothrombine time (PT) 22.2 seconds (INR 2.09) and aPTT 61.7 seconds. The patient also had low random blood glucose 59 mg/dL. Serological tests of HBsAg and Anti HCV Ig were negative.

Abdominal ultrasonography revealed coarseness in echotexture of liver parenchym, signs of cholecystitis with minimal ascites.

Risk factor associated with this potentially fatal complication include co-infection with HIV, hepatitis B or C, pre-existing chronic liver disease, high alcohol intake, malnutrition, advanced age (>35 years old), female sex, and slow acetylators. In our patient, there were risk factors such as, old age (55 years old), malnutrition (thin body and loss of 10 kg body weight), and pre-existing chronic liver disease (liver cirrhosis). Patients over 35 years old have 4 fold increased possibility of developing ATLI. Clinical symptoms of ATLI in United Kingdom reported by Abbaraet et al are nausea and vomiting (54.3%), abdominal pain (18.1%), skin complaints (17.1%), and clinical jaundice (12.4%). Shang et al showed that nausea (41.51%) and vomiting (39.62%) also being the most common symptom in ATLI followed by anorexia, dizziness, abdominal symptptoms, rash/pruritis, fatigue, jaundice, and dark urine. Although nausea, anorexia, and vomiting are not specific to ATLI diagnosis, they might help clinician be more cautious about ATLI. On the other hand, there was 33.02% of ATLI patients who had asymptomatic transaminase elevation. Liver injury could be fatal when it is not recognized early or therapy is not interrupted in time. In our patient, he had nausea, fatigue, jaundice, loss of appetite, dark urine, and pale stools within three days before admission. These symptoms are consistent with clinical data above.

Liver injury occurred in our patient when he was on the first month of ATT treatment. The first line ATTregimen (HRZE) was used. Reported in a population based prospective study in China, 71.59 % of ATLI cases were identified within 2 months after starting anti-TB treatment. The median interval between the initiation of TB treatment and the detection of ATLI was 52.5 (IQR 30, 63). Shorter median time of onset of DILI was 12 days (4-34 days). This has been observed in cirrhosis patient with ATT regimen in India. Vigilant clinical and biochemical monitoring are mandatory to improve the outcomes of cirrhosis patients with ATT therapy. Liver function test showed high ALT (107 U/L) and high AST (144 U/L), high total bilirubin (18.15 mg/dL) with direct bilirubin (10 mg/dL) predominantly. However, level of ALP and GGT were normal. These results fulfilled the diagnostic criteria of ATLI by US DILI network. Low serum protein (4.8 gr/dL) with low albumin (1.5 gr/dL), prolonged prothrombine time (PT; 22.2 seconds) and INR (2.09), and hypoglycemia indicated that there was liver production capacity impairment in liver cirrhosis. Our patient was assessed as Child-Turcotte-Pugh (CTP) grade C (score 12).

There remains ongoing debate as to an adequate definition of drug induced liver injury (DILI). Diagnostic criteria of DILI by US DILI network are elevation of ALT/AST more than five times ULN, or more than three times ULN with jaundice. Deparbhavi et al used other but similar criteria for DILI, i.e. (i) Documented exposure to anti-tuberculous drugs, isoniazid, rifampin, pyrazinamide, ethambutol resulting in hepatotoxicity, defined as recent onset abnormalities in liver tests (rise in bilirubin of at least 2 mg/dL, or AST or ALT > 3x ULN) or ALP> 2x ULN and (ii) Exclusion of other competing cause such as acute hepatitis A, B, C and E, autoimmune hepatitis and bile duct obstruction. ALP based criteria potentially being affected by TB infection related cholestasis and hence may not be
indicative of true DILI.\(^1\)\(^\text{10}\) Sharma et al reported similar findings with our patient, median and range value in patients with cirrhosis and tuberculosis as followed: ALT (61±42 U/L), AST (76±54 U/L), total bilirubin (4.8±6.1 mg/dL), INR (1.8±0.7), CTP score (8.5±1.5).\(^1\)\(^\text{11}\) The phenomenon of liver adaptation or tolerance with mild liver transaminases increases remaining below the threshold values of liver injury is commonly observed during treatment with drugs such as statin and antituberculous medications, especially isoniazid. Despite drug continuation, liver transaminases remain stable or return to normal range, and this should not exclude the drug as likely cause of acute liver injury.\(^1\)\(^\text{12}\)

Diagnosis of ATLI in cirrhotic patient is difficult because it requires the ruling out of other possibilities such as viral hepatitis or other possible causes of hepatotoxicity, elevated enzymes and bilirubin at baseline and fluctuations in enzymes level caused by underlying liver diseases may confound the diagnosis.\(^1\)\(^\text{13}\)\(^\text{14}\) As these drugs are metabolized in the liver, there is a theoretical risk of increased hepatotoxicity in patients with underlying chronic liver disease (CLD). ATT constitutes an important acute precipitating event in decompensation of underlying known or unknown liver disease in India.\(^1\)\(^\text{15}\)\(^\text{16}\) Our patient had no alcoholic drinking habit, no history of injecting drug abuse or blood transfusion recipient. Serological tests of HBsAg and Anti HCV IG were negative. Due to our laboratory limitation, we did not test for autoantibody marker and other serological markers. Diagnostic problems of DILI may therefore be solved in patients with pre-existing infections by hepatotropic viruses, since assessment of the viral load could indicate hepatitis flares rather than DILI.\(^1\)\(^\text{17}\)\(^\text{18}\) The implicated ATDs should be restarted one at a time after the AST concentration has returned to less than twotimes the upper limit of normal. After ALT returns to lessthan two times the ULN, RIF may be restarted with or without EMB. RIF should be restarted first because it ismuch less likely to cause hepatotoxicity than INH and is a highly effective agent. ATD should be reintroducedin lower doses than were used in the initial therapy, e.g., INH 50 mg and RIF 150 mg and then stepped up (e.g., 50–100 mg for INH and 150 mg for RIF) every 3–4 days gradually to the recommended therapeutic doses. We donot recommend the reintroduction of PZA and shouldbe permanently discontinued. If symptoms recur or ALT increases, the last drug added should be stopped. In patientswith elevated baseline ALT from preexisting liver disease, drugs should be restarted when the ALT returns tonear baseline levels in the manner described above.\(^1\)\(^\text{19}\)

4. Conclusions

Anti tuberculosis therapy should be given cautiously in patient with pre-existing liver disease. Liver function derangement usually occurred in the first and second month of ATT as initial phase. Symptoms are not specific but most of patients complain nausea, anorexia, and vomiting. Comprehensive laboratory studies are needed as to exclude other possible causalities. Drugs cessation and monitoring of clinical symptoms and liver function profiles is recommended. Re-introduction and continuing ATT could be done with close supervision.

References


Volume 6 Issue 8, August 2017

www.ijsr.net

Licensed Under Creative Commons Attribution CC BY